CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-30 | Thompson Peter A. Director | Purchase | +312,500 | $16.00 | $5.0M | 13,359,456 |
| 2021-03-30 | Thompson Peter A. Director | Conversion · Series A Preferred Stock | −8,187,100 | 0 | ||
| 2021-03-30 | Thompson Peter A. Director | Conversion · Series B-1 Preferred Stock | −1,572,960 | 0 | ||
| 2021-03-30 | Thompson Peter A. Director | Conversion · Series B-2 Preferred Stock | −1,301,626 | 0 | ||
| 2021-03-30 | Thompson Peter A. Director | Conversion · Series C Preferred Stock | −1,668,350 | 0 | ||
| 2021-03-30 | Thompson Peter A. Director | Conversion · Series C Preferred Stock | −272,724 | 0 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion | +12,730,036 | 13,046,956 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion | +272,724 | 272,724 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Purchase | +46,875 | $16.00 | $750K | 319,599 |
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Purchase | +312,500 | $16.00 | $5.0M | 13,359,456 |
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −8,187,100 | 0 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion · Series B-1 Preferred Stock | −1,572,960 | 0 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion · Series B-2 Preferred Stock | −1,301,626 | 0 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −1,668,350 | 0 | ||
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −272,724 | 0 | ||
| 2021-03-30 | Novo Holdings A/S 10% owner | Conversion | +4,962,207 | 4,962,207 | ||
| 2021-03-30 | Novo Holdings A/S 10% owner | Purchase | +625,000 | $16.00 | $10.0M | 5,587,207 |
| 2021-03-30 | Novo Holdings A/S 10% owner | Conversion · SERIES B-1 CONVERTIBLE PREFERRED STOCK | −2,359,440 | 0 | ||
| 2021-03-30 | Novo Holdings A/S 10% owner | Conversion · SERIES B-2 CONVERTIBLE PREFERRED STOCK | −1,952,439 | 0 | ||
| 2021-03-30 | Novo Holdings A/S 10% owner | Conversion · SERIES C CONVERTIBLE PREFERRED STOCK | −650,328 | 0 |
Page 25 of 26 · 509 trades